4-hydroxybutyric acid analogs

Patent metadata

Field	Value
Publication number	US-9309182-B2
Application number	US-201414255331-A
Country	US
Kind code	B2
Filing date	Apr 17, 2014
Priority date	Feb 14, 2011
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

First claim

What is claimed is:

1. A pharmaceutical composition comprising an effective amount of a compound of Formula IV-a, wherein the compound of Formula IV-a is represented by the following structural formula:

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

2. The composition of claim 1 , additionally comprising a second therapeutic agent selected from the group consisting of a dual serotonin-norepinephrine reuptake inhibitor and an alpha2-delta subunit calcium channel modulator.

3. The composition of claim 2 , wherein the second therapeutic agent is selected from the group consisting of duloxetine, milnacipran, venlafaxine, pregabalin, gabapentin, and a prodrug thereof.

4. The composition of claim 1 wherein the composition is pyrogen-free.

5. The composition of claim 1 wherein the pharmaceutically acceptable salt is a sodium salt.

6. The composition of claim 5 where the compound has an isotopic abundance at each position indicated as “D” of at least 75%.

7. The composition of claim 6 where the compound has an isotopic abundance at each position indicated as “D” of at least 95%.

8. The composition of claim 5 where the compound has an isotopic abundance at each position indicated as “D” of at least 82.5%.

9. The composition of claim 5 where the compound has an isotopic abundance at each position indicated as “D” of at least 90%.

10. The composition of claim 5 where the compound has an isotopic abundance at each position indicated as “D” of at least 97%.

11. A method of treating a disease or disorder selected from the group consisting of excessive daytime sleepiness (EDS), narcolepsy with cataplexy, and obstructive sleep apnea syndrome, comprising the step of administering to a patient in need of such treatment an effective amount of the composition of claim 1 .

12. The method of claim 11 comprising the additional step of administering to the patient in need thereof a second therapeutic agent selected from the group consisting of a dual serotonin-norepinephrine reuptake inhibitor and an alpha2-delta subunit calcium channel modulator.

13. The method of claim 12 , wherein the second therapeutic agent is selected from the group consisting of duloxetine, milnacipran, venlafaxine, pregabalin, gabapentin, and a prodrug thereof.

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Tung Roger D
• Morgan Adam J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title